Galera Therapeutics, Inc. announced on August 9, 2023, Mark Bachleda, Pharm.D., the Company's Chief Commercial Officer, was informed that his position was being eliminated in connection with the Workforce Reduction. In connection with Dr. Bachleda's separation from the Company, the Company expects to enter into a separation agreement with Dr. Bachleda pursuant to which Dr. Bachleda will be eligible to receive the severance payments and benefits under his employment agreement with the company in exchange for executing a general release of claims in favor of the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1826 USD | -1.88% | -5.88% | +25.58% |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Mar. 28 | Galera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+25.58% | 10.12M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- GRTX Stock
- News Galera Therapeutics, Inc.
- Galera Therapeutics, Inc. Announces Elimination of Mark Bachleda, Pharm.D., Chief Commercial Officer